In-Vitro Diagnostic Market by Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and by End User (Stand Alone Laboratory, Hospitals, Academics and Medical Schools, Point of Care Testing, and Other End Users) – Global Opportunity Analysis and Industry Forecast, 2024–2030

In-vitro Diagnostic Market Overview

The global In-Vitro Diagnostic (IVD) Market size was valued at USD 83.63 billion in 2023 and is predicted to reach USD 114.02 billion by 2030, with a CAGR of 4.2% from 2024 to 2030. The IVD market includes a range of medical devices and tests used to diagnose diseases or conditions from samples such as blood, urine, or tissue, without the need for invasive procedures. This market includes various test types such as clinical chemistry, molecular diagnostics, immunoassays, hematology, microbiology, and coagulation, utilizing technologies such as PCR, next-generation sequencing, microarrays, mass spectrometry, and immunoassays.

IVDs are crucial for disease diagnosis, monitoring chronic conditions, guiding treatment decisions, and disease screening in areas such as oncology, infectious diseases, cardiology, diabetes, and genetic disorders. These diagnostics are employed in diverse healthcare settings, including hospitals, laboratories, and outpatient clinics, playing a vital role in modern healthcare by enabling accurate and timely medical decisions.

Increasing Prevalence of Chronic and Infectious Diseases Boost the Market Growth

The rising prevalence of chronic and infectious diseases, including cancer, cardiovascular diseases, diabetes, and various infections is primarily propelling the demand for diagnostic tests in the IVD market. As healthcare systems strive to address these escalating health challenges, there is a growing emphasis on early detection, disease monitoring, and personalized treatment strategies.

According to the World Health Organization, Noncommunicable diseases (NCDs) are responsible for an alarming 41 million deaths annually, comprising approximately 74% of all global fatalities. Among NCDs, cardiovascular diseases lead the mortality statistics, claiming 17.9 million lives each year, followed by cancers at 9.3 million, chronic respiratory diseases at 4.1 million, and diabetes at 2.0 million.

In-vitro diagnostics, with their ability to provide rapid and accurate diagnostic information, are indispensable in facilitating proactive healthcare interventions and improving patient outcomes. Consequently, the market is poised for substantial expansion as healthcare systems worldwide intensify efforts to combat the burgeoning burden of chronic and infectious diseases.

Growing Aging Population Drives the Market Growth

The aging population, characterized by its increasing prevalence of age-related diseases and conditions worldwide, serves as a primary factor for the IVD market growth. As the population ages, there is a corresponding increase in the prevalence of age-related diseases and conditions, necessitating more frequent diagnostic testing for early detection, monitoring, and management to prevent further progression and complications.

This demographic shift is clearly observable from the projected rise of individuals aged 65 years and older, expected to more than double from 761 million in 2021 to 1.6 billion by 2050 worldwide. As a result, healthcare providers are confronted with the increasing task of meeting the changing healthcare requirements of elderly individuals, driving the need for advanced diagnostic solutions.

Moreover, the specific healthcare demands of the aging population emphasize the necessity for precise diagnostic technologies tailored to individual needs. Therefore, the aging demographic plays a pivotal role in shaping the growth and development of the market, influencing its future trajectory. 

High Costs Associated with R&D and Regulatory Approval Hinders the Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the in-vitro diagnostic market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. This investment encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability.

Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion, which in turn hinders the industry growth.

Introduction of Point-Of-Care Testing Solutions in IVD Creates Ample Opportunities for the Market

Point-of-care testing (POCT) is poised to be a significant opportunity for the IVD market in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

POCT technologies offers rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more. That’s why healthcare providers can quickly assess patients' conditions and make timely treatment decisions. By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

By Type, Reagents Holds the Dominant Share in the In-vitro Diagnostic Market

Reagents hold the dominant share of approximately 60% in the type segment of the IVD market as these are essential components used in various diagnostic tests to detect specific biomarkers or substances indicative of diseases or health conditions. They play a fundamental role in facilitating accurate and reliable test results, thus being indispensable in the diagnostic process.

Additionally, reagents are versatile and can be tailored to accommodate different testing methodologies and platforms, making them widely applicable across a range of diagnostic techniques and technologies. Moreover, the continuous demand for diagnostic testing, driven by factors such as the increasing prevalence of chronic diseases, growing aging population, and expanding healthcare infrastructure globally, further contributes to the dominance of reagents in the in-vitro diagnostic market.

By Application, Gastrointestinal Diseases, Holds the highest CAGR of 6 %

Gastrointestinal diseases boast the highest CAGR of 6%, driven by the widespread prevalence and diversity of conditions such as inflammatory bowel disease (IBD), gastroenteritis, and gastrointestinal cancers. This future growth is also supported by advanced diagnostic techniques including stool analysis, which employs microscopy and biochemical tests to identify infections, inflammation, and malabsorption markers.

Additionally, serological tests such as ELISA and Western blot detect specific antibodies or proteins linked to conditions such as celiac disease or IBD, while PCR assays identify pathogens including Helicobacter pylori and viruses. These sophisticated diagnostic tools enhance the accuracy and management of gastrointestinal disorders, contributing significantly to the IVD market expansion.

North America Region Dominates the In-vitro Diagnostic Market 

The North America region holds around 40% of the global IVD market share due to the rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer. According to the National Association of Chronic Disease Directors, cardiovascular diseases account for one out of every three deaths in the U.S., totaling 859,000 deaths annually. This significant burden has increased the demand for IVDs, which are crucial for diagnosing, monitoring, and managing chronic diseases. 

Innovative technologies and advancements in diagnostic techniques enable healthcare providers to better identify at-risk individuals, tailor treatment plans to individual needs, and improve patient outcomes. Moreover, the presence of prominent companies such as Bio-Rad Laboratories Inc., Becton, Dickinson and Company, Abbott Laboratories, and Quest Diagnostics drives market growth through innovation, R&D activities, and collaborations. 

For example, in January 2023, Bio-Rad Laboratories Inc. introduced the CFX Opus 96 Dx Real-Time PCR System, a product approved by the U.S. Food and Drug Administration (FDA) and compliant with European Union regulations for in-vitro diagnostic medical devices. This system features a user-friendly interface and intuitive software, which simplifies operation and minimizes training requirements for lab staff, which in turn boost the market growth. 

Asia-Pacific is Expected to Show Steady Growth in the In-vitro Diagnostic Market Share with a CAGR of 5.4%

The Asia-Pacific region is anticipated to experience the highest growth rate primarily due to rapidly aging population. As individuals age, their susceptibility to chronic diseases such as cardiovascular conditions, diabetes, and neurological disorders increases, necessitating early detection, accurate diagnosis, and personalized treatment options.

For instance, Japan serves as a prominent example, where over 10% of the population is currently aged 80 or above, and approximately one-third, totaling an estimated 36.23 million people, are aged over 65. This demographic shift not only signifies a profound change in population dynamics but also presents complex healthcare challenges that demand innovative diagnostic solutions.

Moreover, the rising prevalence of cancer in the region is a significant driver for the IVD market. As an example, India witnessed approximately 1,461,427 new cancer cases in 2022, highlighting the urgent need for advanced diagnostic technologies. These solutions play a crucial role in enabling precise cancer diagnosis, monitoring disease progression, and customizing personalized treatment strategies.

Additionally, the robust growth of the medical device market is bolstering the expansion of the healthcare sector in Asia-Pacific. As an example, India’s medical device sector is emerging, with substantial growth in exports and investments in healthcare infrastructure and technology. This growth trajectory facilitates the adoption of advanced diagnostic solutions such as IVDs, enhancing the accessibility, affordability, and quality of diagnostic services across the region.

In fiscal year 2021-22, India's medical device exports reached USD 2.9 billion, marking a notable increase of 15.47% compared to the previous fiscal year. The rise of India's medical device sector has led to greater investment in healthcare infrastructure and technology and enables the way for the adoption of advanced diagnostic solutions such as in-vitro diagnostics, supported by growing exports and demand for healthcare products globally.

Competitive Landscape

Several market players operating in the in-vitro diagnostic industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Note: In others we have also analysis the companies such as DiaSorin, Ortho Diagnostics, Arkray, and others.

These market players are adopting various strategies, including partnerships, collaborations, mergers, acquisitions, and innovative product launches across various regions to maintain their dominance in the market. These strategies are crucial due to the rapidly evolving technological landscape and the increasing demand for advanced diagnostic solutions.

Test